Status: Not yet recruiting
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
The purpose of this study is to assess the safety and tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in untreated, unresectable or metastatic melanoma participants in India
Participants needed: 30
Trial details
Phase: Phase 4Age: 12+Biological sex: AllType: InterventionalSponsor: Bristol-Myers SquibbUpdated: Mar 9, 2026Locations: 8
Eligibility criteria
Participants must have an Eastern Cooperative Oncology Group (ECOG) performance... [+5]
Participants must not have active brain metastases or leptomeningeal metastases. [+6]